SOURCE-LINKED STUDY SUMMARY
Liraglutide and Renal Outcomes in Type 2 Diabetes.
Abstract summarizedQuality not appraised
- What was studied
- This prespecified secondary analysis of the randomized LEADER trial compared liraglutide with placebo, added to usual care, for a composite kidney outcome.
- Who / model studied
- The trial randomized 9340 people and followed them for a median 3.84 years.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- The kidney outcome occurred in 268 of 4668 liraglutide recipients versus 337 of 4672 placebo recipients. The difference was driven mainly by less new persistent macroalbuminuria.
- Limitations & context
- The kidney outcome was a secondary composite outcome. The abstract does not provide a formal methodological quality appraisal.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1056/nejmoa1616011